Body-Made CAR-T cells take on Hard-to-Treat myeloma
NCT ID NCT07539233
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new gene therapy called QI-019B for people with multiple myeloma that has returned or not responded to at least two prior treatments. The therapy works by creating cancer-fighting CAR-T cells directly inside the patient's body. The study will enroll 24 participants to check safety and see if the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QI-019B (a gene therapy that creates CAR-T cells inside the body)
What this could lead to
If it works, this could offer a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a very early, small trial (24 people) focused on safety. The treatment may not work, and there are risks like severe immune reactions (cytokine release syndrome) and nerve problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••